Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaker A Mousa

Showing results (61-70 of 435) with videos related to

Pageof 44
Sort By:
Expert Opinion on Therapeutic Targets|January 21, 2022
Modulations of ferroptosis in lung cancer therapyRobert Walters, Shaker A Mousa
Expert Review of Clinical Pharmacology|August 5, 2022
Colony stimulating factors for prophylaxis of chemotherapy-induced neutropenia in childrenHeeyeon Kim, Shaker A Mousa
Ophthalmology and Eye Diseases|July 18, 2013
Bevasiranib for the treatment of wet, age-related macular degenerationAdinoyi O Garba, Shaker A Mousa
Biomedicines|December 30, 2020
Pharmacotherapy in COVID 19: Potential Impact of Targeting the Complement SystemCourtney M Barkoff, Shaker A Mousa
Neural Regeneration Research|January 29, 2019
Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agentsShaker A Mousa, Bassam M Ayoub
Current Pharmaceutical Design|February 3, 2004
Angiogenesis inhibitors: current & future directionsShaker A Mousa, Ahmed S Mousa
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 10, 2010
Current status of vascular endothelial growth factor inhibition in age-related macular degenerationShaker A Mousa, Shaymaa S Mousa
Critical Reviews in Oncology/Hematology|May 17, 2019
Current management of neuroblastoma and future directionElizabeth R Pastor, Shaker A Mousa
Infection and Drug Resistance|June 23, 2011
Prevention strategies for antimicrobial resistance: a systematic review of the literatureWhitney P Caron, Shaker A Mousa
Retina (Philadelphia, Pa.)|January 19, 2005
Angiogenesis, choroidal neovascularization, and the coagulation systemGlenn L Stoller, Shaker A Mousa
Pageof 44

Showing results (61-70 of 435) with videos related to

Sort By:
Pageof 44
Expert Opinion on Therapeutic Targets|January 21, 2022
Modulations of ferroptosis in lung cancer therapyRobert Walters, Shaker A Mousa
Expert Review of Clinical Pharmacology|August 5, 2022
Colony stimulating factors for prophylaxis of chemotherapy-induced neutropenia in childrenHeeyeon Kim, Shaker A Mousa
Ophthalmology and Eye Diseases|July 18, 2013
Bevasiranib for the treatment of wet, age-related macular degenerationAdinoyi O Garba, Shaker A Mousa
Biomedicines|December 30, 2020
Pharmacotherapy in COVID 19: Potential Impact of Targeting the Complement SystemCourtney M Barkoff, Shaker A Mousa
Neural Regeneration Research|January 29, 2019
Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agentsShaker A Mousa, Bassam M Ayoub
Current Pharmaceutical Design|February 3, 2004
Angiogenesis inhibitors: current & future directionsShaker A Mousa, Ahmed S Mousa
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 10, 2010
Current status of vascular endothelial growth factor inhibition in age-related macular degenerationShaker A Mousa, Shaymaa S Mousa
Critical Reviews in Oncology/Hematology|May 17, 2019
Current management of neuroblastoma and future directionElizabeth R Pastor, Shaker A Mousa
Infection and Drug Resistance|June 23, 2011
Prevention strategies for antimicrobial resistance: a systematic review of the literatureWhitney P Caron, Shaker A Mousa
Retina (Philadelphia, Pa.)|January 19, 2005
Angiogenesis, choroidal neovascularization, and the coagulation systemGlenn L Stoller, Shaker A Mousa
Pageof 44